Cancer Support Group

Sunday, Nov 17th

Last update:06:42:40 AM GMT

Home News and Update Year 2010 Experimental Vaccine May Delay Bowel Inflammation and Colon Cancer

Experimental Vaccine May Delay Bowel Inflammation and Colon Cancer

DNA
25 March 2010
Washington, DC

A new experimental vaccine could delay bowel inflammation and colon cancer, researchers at the University of Pittsburgh School of Medicine say.

Their findings have appeared in Cancer Prevention Research, a journal of the American Association for Cancer Research.

According to senior author Olivera Finn, professor and chair, Department of Immunology, Pitt School of Medicine, people with chronic inflammatory disorders such as IBD are at greater risk for developing cancer at the inflamed site. In other cases, genes that develop cancerous changes can trigger inflammation.

The vaccine made by her team is directed against an abnormal variant of a self-made cell protein called MUC1, which is altered and produced in excess in both IBD and colon cancer.

Dr Finn said: “Our experiments indicate that boosting the immune response against this protein early in the disease can delay IBD development, control inflammation and thereby reduce the risk of future cancers.”

“These findings suggest also that the early stages of chronic inflammation might be considered a premalignant condition.”

For the study, the scientists tested transgenic mice that spontaneously develop IBD and then progress to colitis-associated colon cancer, producing the human version of MUC1 in both disease states. It was seen that animals that received the vaccine showed the first signs of IBD significantly later than those in two control groups that did not get the vaccine.

Microscopic evaluation of the colon tissue demonstrated less inflammation in the vaccinated mice, and no indication of cancerous changes. Nearly half of the animals in each of the control groups had evidence of abnormal tissue, and two had colon cancer.

Dr Finn said: “The MUC1 vaccine seems to change the local environment from one that promotes cancer development to one that inhibits it.”

“Certain immune cells that we usually see in the inflamed colon aren’t present, and that could make the surroundings less friendly for potentially cancerous cells that also are directly targeted by the vaccine for destruction.”

Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.

Suggestions

This is YOUR sites, so if you have suggestions or feedback on how we can improve it for you, please let us know! We do our best to keep up!

Make a Suggestion
Manthan Award

Link to Aarogya

aarogya logo
NASSCOM Award